Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis

Scott S. Short, Jin Wang, Shannon L. Castle, G. Esteban Fernandez, Nancy Smiley, Michael Zobel, Elizabeth M. Pontarelli, Stephanie C. Papillon, Anatoly V. Grishin, Henri Ford

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The intestinal barrier becomes compromised during systemic inflammation, leading to the entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E 2 (PGE 2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction (TJ)-associated proteins junction-associated molecule-A and zonula occludens-1. Luminal instillation of PGE 2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5-1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE 2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising TJs. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients.

Original languageEnglish (US)
Pages (from-to)1265-1275
Number of pages11
JournalLaboratory Investigation
Volume93
Issue number12
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Celecoxib
Cyclooxygenase 2
Peritonitis
Cyclooxygenase 2 Inhibitors
Prostaglandins E
Prostaglandins
Mucous Membrane
Tight Junction Proteins
Bacterial Translocation
Tight Junctions
Intestinal Mucosa
Critical Care
Punctures
Critical Illness
Ligation
Sepsis
Inflammation
Bacteria
Injections
Enzymes

Keywords

  • Celecoxib
  • cyclooxygenase-2
  • gut barrier failure
  • gut origin sepsis
  • peritonitis
  • prostaglandin E2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology
  • Medicine(all)

Cite this

Short, S. S., Wang, J., Castle, S. L., Fernandez, G. E., Smiley, N., Zobel, M., ... Ford, H. (2013). Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis. Laboratory Investigation, 93(12), 1265-1275. https://doi.org/10.1038/labinvest.2013.119

Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis. / Short, Scott S.; Wang, Jin; Castle, Shannon L.; Fernandez, G. Esteban; Smiley, Nancy; Zobel, Michael; Pontarelli, Elizabeth M.; Papillon, Stephanie C.; Grishin, Anatoly V.; Ford, Henri.

In: Laboratory Investigation, Vol. 93, No. 12, 01.12.2013, p. 1265-1275.

Research output: Contribution to journalArticle

Short, SS, Wang, J, Castle, SL, Fernandez, GE, Smiley, N, Zobel, M, Pontarelli, EM, Papillon, SC, Grishin, AV & Ford, H 2013, 'Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis', Laboratory Investigation, vol. 93, no. 12, pp. 1265-1275. https://doi.org/10.1038/labinvest.2013.119
Short SS, Wang J, Castle SL, Fernandez GE, Smiley N, Zobel M et al. Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis. Laboratory Investigation. 2013 Dec 1;93(12):1265-1275. https://doi.org/10.1038/labinvest.2013.119
Short, Scott S. ; Wang, Jin ; Castle, Shannon L. ; Fernandez, G. Esteban ; Smiley, Nancy ; Zobel, Michael ; Pontarelli, Elizabeth M. ; Papillon, Stephanie C. ; Grishin, Anatoly V. ; Ford, Henri. / Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis. In: Laboratory Investigation. 2013 ; Vol. 93, No. 12. pp. 1265-1275.
@article{6f941c5e3a96446e84e50741cd251670,
title = "Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis",
abstract = "The intestinal barrier becomes compromised during systemic inflammation, leading to the entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E 2 (PGE 2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction (TJ)-associated proteins junction-associated molecule-A and zonula occludens-1. Luminal instillation of PGE 2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5-1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE 2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising TJs. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients.",
keywords = "Celecoxib, cyclooxygenase-2, gut barrier failure, gut origin sepsis, peritonitis, prostaglandin E2",
author = "Short, {Scott S.} and Jin Wang and Castle, {Shannon L.} and Fernandez, {G. Esteban} and Nancy Smiley and Michael Zobel and Pontarelli, {Elizabeth M.} and Papillon, {Stephanie C.} and Grishin, {Anatoly V.} and Henri Ford",
year = "2013",
month = "12",
day = "1",
doi = "10.1038/labinvest.2013.119",
language = "English (US)",
volume = "93",
pages = "1265--1275",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis

AU - Short, Scott S.

AU - Wang, Jin

AU - Castle, Shannon L.

AU - Fernandez, G. Esteban

AU - Smiley, Nancy

AU - Zobel, Michael

AU - Pontarelli, Elizabeth M.

AU - Papillon, Stephanie C.

AU - Grishin, Anatoly V.

AU - Ford, Henri

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The intestinal barrier becomes compromised during systemic inflammation, leading to the entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E 2 (PGE 2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction (TJ)-associated proteins junction-associated molecule-A and zonula occludens-1. Luminal instillation of PGE 2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5-1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE 2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising TJs. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients.

AB - The intestinal barrier becomes compromised during systemic inflammation, leading to the entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E 2 (PGE 2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction (TJ)-associated proteins junction-associated molecule-A and zonula occludens-1. Luminal instillation of PGE 2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5-1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE 2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising TJs. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients.

KW - Celecoxib

KW - cyclooxygenase-2

KW - gut barrier failure

KW - gut origin sepsis

KW - peritonitis

KW - prostaglandin E2

UR - http://www.scopus.com/inward/record.url?scp=84888317784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888317784&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2013.119

DO - 10.1038/labinvest.2013.119

M3 - Article

C2 - 24126890

AN - SCOPUS:84888317784

VL - 93

SP - 1265

EP - 1275

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 12

ER -